New analysis shows that abbott's freestyle libre® system provides similar and sustained reductions in glucose levels for people with both type 1 and type 2 diabetes

Meta-analysis of 75 real-world studies found that abbott's freestyle libre system is associated with significant reductions in glycated hemoglobin (hba1c) at three months1 reductions in hba1c followed a similar pattern in people with both type 1 and type 2 diabetes and were sustained for up to 24 months1 meta-analysis shows that people with type 2 diabetes who use insulin benefit from the freestyle libre system in the same way as people with type 1 diabetes in real-world studies1, showing the need for access to the latest glucose monitoring technology abbott park, ill., april 28, 2022 /prnewswire/ -- abbott (nyse: abt) today announced results from a new meta-analysis of 75 real-world, observational studies demonstrating that its freestyle® libre system provides significant reductions in glycated hemoglobin (hba1c) that are sustained up to 24 months in adults with both type 1 and type 2 diabetes.1 people with type 2 diabetes who use insulin are often restricted when it comes to access to continuous glucose monitoring, but both clinical trials and real-world studies demonstrate significant improvement of glycemic control.
ABT Ratings Summary
ABT Quant Ranking